Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
Adam J. Wolpaw, Yaël P. Mossé(Children's Hospital of Philadelphia), Stefan Knapp(Goethe University Frankfurt), David Levens(National Cancer Institute), Gabriele Büchel(University of Würzburg), Linda Z. Penn(Princess Margaret Cancer Centre), Julie R. Park(Seattle Children's Hospital), Martine F. Roussel(St. Jude Children's Research Hospital), Natalia Jura(QB3), Seychelle M. Vos(Howard Hughes Medical Institute), Michael Rapé(Howard Hughes Medical Institute), Martin Eilers(University of Würzburg), Steven J. Metallo(Georgetown University), William P. Tansey(Vanderbilt University), Richard Bayliss(University of Leeds), Kliment A. Verba(University of California, San Francisco), Ronen Marmorstein(University of Pennsylvania), Chi V. Dang(Abramson Center for Jewish Life), William A. Weiss(City College of San Francisco), Mark A. Lemmon(Yale Cancer Center), Kevan M. Shokat(Howard Hughes Medical Institute), Elmar Wolf(Hochschule für Angewandte Wissenschaften Kiel), Gwenn M. Hansen(Nurix (United States)), W. Clay Gustafson(Revolution Medicines (United States)), John M. Maris(Children's Hospital of Philadelphia)
Cited by 70
Related Papers
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
|Nature|2013|2.5k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
|Cell|2012|1.7k
RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels
|Nature|2007|1.6k
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
|Science|2007|1.4k